In summary, this study verified that METTL3 and WTAP are factors indicating poor prognosis in patients with AML; METTL3 is an independent prognostic factor, and receiving HSCT can improve the prognosis of patients with positive METTL3 and WTAP expression. The gene discussed is METTL3; the disease is acute myeloid leukemia.